MENU

Why these 4 shares are getting hammered today

After a pretty subdued start to the trading week, the S&P/ASX 200 (Index: ^AXJO) (ASX:XJO) has managed to bounce-back into positive territory thanks to a rally from the big miners.

At lunchtime, the benchmark index was trading 0.15% higher to 5,738 points.

Four shares that have been under heavy pressure today include:

Navitas Limited (ASX: NVT)

The Navitas share price has slumped more than 15% today after the education provider announced it is likely to take a big earnings hit as a result of unfavourable changes to the Adult Migrant English Program. Unfortunately, the company’s EBITDA could fall between $12 million to $14 million from FY18 onwards after the government decided it would only recommend Navitas as a preferred tenderer for a reduced number of contract regions starting from July 1 2017.

REA Group Limited (ASX: REA)

The REA Group share priced has dropped more than 2.5% today, after its shares went ex-dividend. However, today’s fall could also be related to an article published in the Fairfax press that has suggested the company has changed its accounting practices on multiple occasions to provide a more favourable comparison with Fairfax Media Limited (ASX: FXJ) owned rival, Domain Group. As highlighted here, REA Group also faces the threat of new entrants in the property market which could have some investors concerned.

Slater & Gordon Limited (ASX: SGH)

The Slater & Gordon share price continues to swing wildly as investors question how much longer the embattled legal firm will be able to operate under the current regime. The shares have lost another 8% today and are now trading at just 9 cents a share. Unfortunately, speculation is the key driver of the share price right now and it looks as though investors should avoid Slater & Gordon at all costs.

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price has crashed 4.2% today, despite no notable news from the company. Unfortunately, an impressive first-half result has not been enough to get the support of investors, with the ongoing investigation into price fixing still the overwhelming concern. Interestingly, Mayne Pharma is now the 11th most shorted share on the ASX with around 9.6% of shares under the control of short sellers.

For Investors Who Are Anxious About 2017

In 2017, the share market could have its most volatile year ever. That's why one Foolish expert is revealing 5 of his favorite dividend payers now. These "strong and steady" shares promise a healthy stream of income plus capital gains...

But you must act now. This newly updated report is available for a limited time only, and your copy is 100% free. So don't miss out!

Simply click here to receive your free copy of "Our Top 5 ASX Dividend Shares to Earn You Money in 2017" right now.

Motley Fool contributor Christopher Georges owns shares of Mayne Pharma Group Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

HOT OFF THE PRESSES: My #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.